Analysts’ Weekly Ratings Changes for Freenome (FRNM)

A number of research firms have changed their ratings and price targets for Freenome (NASDAQ: FRNM):

• 8/20/2026 – Freenome is now covered by Guggenheim. They set a “buy” rating and a $21.00 price target on the stock.
• 8/20/2026 – Freenome is now covered by Guggenheim. They set a “buy” rating and a $21.00 price target on the stock.
• 8/18/2026 – Freenome is now covered by TD Cowen. They set a “buy” rating and a $17.00 price target on the stock.
• 8/18/2026 – Freenome is now covered by TD Cowen. They set a “buy” rating and a $17.00 price target on the stock.
• 8/17/2026 – Freenome is now covered by BTIG Research. They set a “buy” rating and a $17.00 price target on the stock.
• 8/17/2026 – Freenome is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $17.00 price target on the stock.
• 8/17/2026 – Freenome is now covered by Jefferies Financial Group Inc.. They set a “buy” rating and a $17.00 price target on the stock.
• 8/17/2026 – Freenome is now covered by BTIG Research. They set a “buy” rating and a $17.00 price target on the stock.
• 8/14/2026 – Freenome is now covered by Leerink Partners. They set an “outperform” rating and a $18.00 price target on the stock.

Freenome is a biotechnology company developing blood-based tests designed to detect cancer at earlier, more treatable stages. The company combines artificial intelligence with multiomics analysis, examining biological signals in blood—including genetic, immune and other molecular indicators—to identify cancer-related patterns.

Freenome’s research and development efforts have focused on noninvasive screening for colorectal cancer, with additional programs targeting other cancers. Its platform is intended to support earlier detection and may also have applications in cancer monitoring and treatment-related decision-making.

Founded in 2014 and based in California, Freenome has pursued collaborations with healthcare and biopharmaceutical organizations to advance its testing technology.